Key facts
- Ecor1 Capital is a hedge fund based in San Francisco, CA with 15 tracked portfolio companies.
- Notable positions include Freenome, Eikon Therapeutics (NAS: EIKN), ReCode Therapeutics, Cellares, Dewpoint Therapeutics.
- The team roster lists 1 person.
- Ecor1 Capital reports $669.0M in regulatory assets under management across 3 private funds, per its SEC Form ADV (2026-03).
Registered with the SEC
Form ADV · 2026-03 · CRD 167121- Regulatory AUM
- $669.0M
- Private fund assets
- $3.4B
- Private funds
- 3 · 1 venture, 2 hedge
- Staff
- 22
- Registered office
- SAN FRANCISCO, CA
- SEC status
- Approved
Discloses a disciplinary history on Form ADV. Reports custody of client assets.
Source: SEC Investment Adviser Public Disclosure, Form ADV (registered as ECOR1 CAPITAL, LLC).
Free account
See the whole book
- ·The book's top 25 — of 15 recorded positions
- ·Watchlist + alerts for Ecor1 Capital's activity
Create free account
No card required
Portfolio, priced
15 companies · by our current valuations| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | |
| Eikon Therapeutics (NAS: EIKN) | — | $971.7M | — | |
| ReCode Therapeutics | — | $700.0M | — | |
| Cellares | — | $675.0M | — | |
| Dewpoint Therapeutics | — | $500.0M | — | |
| Diagonal Therapeutics | Drug Discovery | $458.5M | — | |
| Attovia Therapeutics | — | $370.0M | — | |
| Ashvattha Therapeutics | — | $310.0M | — | |
| Ajax Therapeutics | Drug Discovery | $192.5M | — | |
| Omniox | — | $150.0M | — | |
| Affinia Therapeutics | — | $145.0M | — | |
| Actio Biosciences | — | $137.0M | — | |
| Epikast | — | $37.2M | — | |
| Aktis Oncology | Drug Discovery | — | — | |
| Terremoto Biosciences | — | — | — |
Team
1 people on record — 1 with verified contacts
Partners, principals, and the people who answer a pitch. Pro members reveal contacts with credits.
Frequently asked
- What companies does Ecor1 Capital invest in?
- Ecor1 Capital has 15 recorded portfolio companies, including Freenome, Eikon Therapeutics (NAS: EIKN), ReCode Therapeutics, Cellares.